Roberto Sabbatini

Roberto Sabbatini

Auto-generated profile, based on publicly available information

Roberto Sabbatini

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
UGUgo De Giorgi
Ugo De Giorgi
GPGiuseppe Procopio
Giuseppe Procopio
DGDiana Giannarelli
Diana Giannarelli
RSRoberto Sabbatini
Roberto Sabbatini
ABAlessandra Bearz
Alessandra Bearz
CSCora N. Sternberg
Cora N. Sternberg
Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR) </≥ 3, systemic immune inflammation index (SII) </≥ 1,375, and platelet-to-lymphocyte ratio (PLR) </≥ 232. Patients were classified as high BMI (≥25 kg/m2) versus normal BMI (<25 kg/m2). Results: Among 313 evaluable patients, 235 (75.1%) were male, and median age was 65 years (range, 40–84 years), with 105 (33.69%) ≥70 years. In univariate analysis, age, performance status, BMI, SII, NLR, and PLR were able to predict outcome. In multivariate analyses, SII ≥1,375, BMI <25 kg/m2, and age ≥70 years independently predicted overall survival [OS; HR = 2.96, 95% confidence interval (CI), 2.05–4.27; HR = 1.59, 95% CI, 1.10–2.30; and HR = 1.65, 95% CI, 1.07–2.55, respectively). A patient with both SII ≥1,375 and BMI <25 kg/m2 was estimated to have much worse OS (HR, 3.37; 95% CI, 2.29–4.95; P <0.0001) than a patient with neither or only one risk factor. SII changes at 3 months predicted OS (P <0.0001). Conclusions: Normal BMI combined with inflammation tripled the risk of death, suggesting that these biomarkers are critical prognostic factors for OS in patients with RCC treated with nivolumab.

1 March 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
AGAnnalisa Guida
Annalisa Guida
RSRoberto Sabbatini
Roberto Sabbatini
LGLara Gibellini
Lara Gibellini
SBSara De Biasi
Sara De Biasi
ACAndrea Cossarizza
Andrea Cossarizza
CPCamillo Porta
Camillo Porta